Identification of Gene Signature for Renal Cell Carcinoma-Associated Fibroblasts Mediating Cancer Progression and Affecting Prognosis

Bitian Liu,Yunhong Zhan,Xiaonan Chen,Shen Pan,Bin Wu

doi:10.2139/ssrn.3688868

Abstract

Identification of Gene Signature for Renal Cell Carcinoma-Associated Fibroblasts Mediating Cancer Progression and Affecting Prognosis

Highlights

Cancer-associated fibroblasts (CAFs) are most abundant in stroma and are critically involved in cancer progression
In summary, our findings indicate that the gene signature potentially serves as a biomarker of CAFs in renal cell carcinoma (RCC) and that infiltration of fibroblasts in RCC is an independent prognostic factor associated with pathological grade and stage of tumor
In EPIC, the proportion of CAFs showed a tendency to increase with tumor stage and grade progression, but the proportion of CD4+ and CD8+ T cells had no significant change in kidney renal clear cell carcinoma (KIRC) (Figure 1B)

Summary

Introduction

Cancer-associated fibroblasts (CAFs) are most abundant in stroma and are critically involved in cancer progression. The specific signature of CAFs and related clinicopathological parameters in renal cell carcinoma (RCC) remain unclear. Renal cell carcinoma (RCC) is one of the ten most deadly cancers in the world, causing more than 140,000 deaths each year[1]. Over the past decade, advanced RCC treatment has changed from a nonspecific immune approach to vascular endothelial growth factor targeted therapy, and to immune checkpoint blockers[2]. The overall prognosis for patients with advanced RCC is still poor[3]. Cancer-associated fibroblasts (CAFs) are an important part of the tumor microenvironment (TME), and they can function as tumor promoters and inhibitors[4].

Methods

Results

Discussion

Conclusion